Mineralys Therapeutics

Historical price data

Mineralys Therapeutics is pioneering a new approach to treating hypertension by targeting aldosterone synthase, a key enzyme in the renin-angiotensin-aldosterone system. The company's lead candidate, lorundrostat, has demonstrated promising results in Phase 2 trials for patients with uncontrolled hypertension, showing significant blood pressure reductions. With a management team experienced in cardiovascular drug development and a clear focus on addressing a major unmet medical need, Mineralys is positioned to advance its clinical programs toward potential regulatory approval. The company's strategy centers on developing targeted therapies that address the root causes of hypertension rather than just managing symptoms.

Proprietary platform for developing highly selective aldosterone synthase (CYP11B2) inhibitors that target the root cause of hypertension while minimizing effects on cortisol production.

6 drugs in pipeline, 2 in Phase 3

Total raised: $350M

Competes against established hypertension drug classes and emerging aldosterone pathway inhibitors from companies like Bayer (finerenone) and AstraZeneca (baxdrostat). Differentiates through lorundrostat's high selectivity for aldosterone synthase, potentially offering better safety profile than less selective competitors or existing mineralocorticoid receptor antagonists.